Cancer AdComm Votes No on Spectrum’s Pozenveo for Orphan Disease Lung Cancer
Spectrum Pharmaceutical’s experimental cancer drug Pozenveo (poziotinib) got the thumbs down from the FDA’s Oncologic Drugs Advisory Committee (ODAC) in a vote of nine to four yesterday. Source: Drug Industry…